Survival was generally good (70% 10‐year survival in Japan; 84% 5‐year survival in Taiwan) [31, 33], but worse in secondary AIHA and patients with DAT‐negative or IgA‐mediated AIHA [23, 31, 34]. Here, CD79A is linked to autoimmune hemolytic anemia.